
Navidea Biopharmaceuticals, Inc. – AMEX:NAVB
Navidea Biopharmaceuticals stock price today
Navidea Biopharmaceuticals stock price monthly change
Navidea Biopharmaceuticals stock price quarterly change
Navidea Biopharmaceuticals stock price yearly change
Navidea Biopharmaceuticals key metrics
Market Cap | 10.00K |
Enterprise value | 6.37M |
P/E | -0.44 |
EV/Sales | 88.39 |
EV/EBITDA | -0.31 |
Price/Sales | 108.23 |
Price/Book | -0.92 |
PEG ratio | N/A |
EPS | -0.09 |
Revenue | N/A |
EBITDA | -9.45M |
Income | -2.53M |
Revenue Q/Q | -100% |
Revenue Y/Y | -99.05% |
Profit margin | -32148.29% |
Oper. margin | -27646.53% |
Gross margin | 96.66% |
EBIT margin | -27646.53% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNavidea Biopharmaceuticals stock price history
Navidea Biopharmaceuticals stock forecast
Navidea Biopharmaceuticals financial statements
Dec 2022 | 610 | -5.52M | -905001.8% |
---|---|---|---|
Mar 2023 | 0 | -793.48K | |
Jun 2023 | 0 | 6.03M | |
Sep 2023 | 0 | -2.25M |
Dec 2022 | 4371606 | 12.51M | 286.28% |
---|---|---|---|
Mar 2023 | 2367586 | 11.91M | 503.26% |
Jun 2023 | 8219812 | 9.00M | 109.57% |
Sep 2023 | 5698794 | 8.67M | 152.29% |
Dec 2022 | -2.43M | -72.03K | -99.76K |
---|---|---|---|
Mar 2023 | -1.72M | -39.40K | -200.53K |
Jun 2023 | 4.69M | -65.00K | 1.48M |
Sep 2023 | -10.24M | -524.65K | -188.57K |
Navidea Biopharmaceuticals alternative data
Aug 2023 | 11 |
---|---|
Sep 2023 | 11 |
Oct 2023 | 11 |
Nov 2023 | 11 |
Dec 2023 | 11 |
Jan 2024 | 11 |
Feb 2024 | 11 |
Apr 2024 | 11 |
May 2024 | 11 |
Jun 2024 | 11 |
Jul 2024 | 11 |
Navidea Biopharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Aug 2022 | 5030 | 1740 |
Jun 2023 | 11969 | 0 |
Patent |
---|
Application Filling date: 30 Dec 2021 Issue date: 30 Jun 2022 |
Grant Utility: Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same Filling date: 10 Oct 2017 Issue date: 28 Jun 2022 |
Application Filling date: 8 Jul 2021 Issue date: 13 Jan 2022 |
Application Filling date: 18 May 2021 Issue date: 4 Nov 2021 |
Application COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS Filling date: 30 Sep 2020 Issue date: 20 May 2021 |
Grant Filling date: 10 Oct 2017 Issue date: 18 May 2021 |
Application COMPOSITIONS AND RELATED METHODS FOR THE ABLATION OF M2 MACROPHAGES AND MYELOID DERIVED SUPPRESSOR CELLS Filling date: 19 Aug 2020 Issue date: 25 Feb 2021 |
Application Filling date: 27 Mar 2020 Issue date: 1 Oct 2020 |
Application Filling date: 27 Jan 2020 Issue date: 30 Jul 2020 |
Quarter | Transcript |
---|---|
Q4 2022 21 Mar 2023 | Q4 2022 Earnings Call Transcript |
Q3 2022 15 Nov 2022 | Q3 2022 Earnings Call Transcript |
Q2 2022 8 Sep 2022 | Q2 2022 Earnings Call Transcript |
Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Michael Stanley Rosol Ph.D. (1968) Senior Vice President & Chief Medical Officer | $282,450 |
-
What's the price of Navidea Biopharmaceuticals stock today?
One share of Navidea Biopharmaceuticals stock can currently be purchased for approximately $0.
-
When is Navidea Biopharmaceuticals's next earnings date?
Unfortunately, Navidea Biopharmaceuticals's (NAVB) next earnings date is currently unknown.
-
Does Navidea Biopharmaceuticals pay dividends?
No, Navidea Biopharmaceuticals does not pay dividends.
-
How much money does Navidea Biopharmaceuticals make?
Navidea Biopharmaceuticals has a market capitalization of 10.00K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 87.65% to 65.65K US dollars.
-
What is Navidea Biopharmaceuticals's stock symbol?
Navidea Biopharmaceuticals, Inc. is traded on the AMEX under the ticker symbol "NAVB".
-
What is Navidea Biopharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Navidea Biopharmaceuticals?
Shares of Navidea Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Navidea Biopharmaceuticals's key executives?
Navidea Biopharmaceuticals's management team includes the following people:
- Dr. Michael Stanley Rosol Ph.D. Senior Vice President & Chief Medical Officer(age: 57, pay: $282,450)
-
How many employees does Navidea Biopharmaceuticals have?
As Jul 2024, Navidea Biopharmaceuticals employs 11 workers.
-
When Navidea Biopharmaceuticals went public?
Navidea Biopharmaceuticals, Inc. is publicly traded company for more then 32 years since IPO on 10 Nov 1992.
-
What is Navidea Biopharmaceuticals's official website?
The official website for Navidea Biopharmaceuticals is navidea.com.
-
Where are Navidea Biopharmaceuticals's headquarters?
Navidea Biopharmaceuticals is headquartered at 4995 Bradenton Avenue, Dublin, OH.
-
How can i contact Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals's mailing address is 4995 Bradenton Avenue, Dublin, OH and company can be reached via phone at +61 47937500.
Navidea Biopharmaceuticals company profile:

Navidea Biopharmaceuticals, Inc.
navidea.comAMEX
11
Biotechnology
Healthcare
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Dublin, OH 43017-3552
CIK: 0000810509
ISIN: US63937X2027
CUSIP: 63937X202